KRRO
Korro Bio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Korro Bio, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 12 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Largest filed tie
0
filed ties
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Korro Bio, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Korro Bio, Inc.'s 6 closest co-movers, none share that code.
Korro Bio, Inc.
16.49
+0.63 · +4.00%
post 16.49 −0.01%
Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| Lynx1 | $20.3M | 10.57% | 0.00% |
| NEA | $17.1M | 8.92% | 0.00% |
| VR Adviser | $13.3M | 6.94% | 0.00% |
| Atlas Venture Life Science | $12.7M | 6.61% | −15.32% |
| Balyasny | $12.5M | 6.54% | −8.49% |
| Manager | Value | % base | |
|---|---|---|---|
| Lynx1 | $20.3M | 10.57% | 0.00% |
| NEA | $17.1M | 8.92% | 0.00% |
| VR Adviser | $13.3M | 6.94% | 0.00% |
| Atlas Venture Life Science | $12.7M | 6.61% | −15.32% |
| Balyasny | $12.5M | 6.54% | −8.49% |
Bull2
Bear1
Expected move
No implied move.